{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Antennapedia", "cell delivery", "liposomal doxorubicin", "size distribution", "tissue distribution", "tumor treatment"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34405574", "DateCompleted": {"Year": "2022", "Month": "03", "Day": "25"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "25"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "08", "Day": "28"}], "Language": ["eng"], "ELocationID": ["10.1002/btpr.3202"], "Journal": {"ISSN": "1520-6033", "JournalIssue": {"Volume": "37", "Issue": "6", "PubDate": {"Year": "2021", "Month": "Nov"}}, "Title": "Biotechnology progress", "ISOAbbreviation": "Biotechnol Prog"}, "ArticleTitle": "Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.", "Pagination": {"StartPage": "e3202", "MedlinePgn": "e3202"}, "Abstract": {"AbstractText": ["The positively-charged peptide antp derived from Antennapedia transcription protein is demonstrated to mediate the liposome translocation across the cell membrane. In the current investigation, we prepared a stable liposomal doxorubicin (Dox) formulation and targeted it with the antp peptide from 0 to 200 ligand/liposome. These antp-containing liposomes were investigated in terms of physical stability on storage in the refrigerator and upon incubation in blood. Also, other features like cell binding, uptake, biodistribution, and treatment efficiency were evaluated in C26 colon carcinoma BALB/c mice. The Antp in liposomes resulted in enhanced particle growth with the development of the enormously large liposomes from 2000 to 6000\u2009nm. Upon incubation in blood, these large liposomes were removed. The antp also enhanced the cell binding affinity and cell uptake rate of the liposomes and resulted in the restriction of the cancer cell proliferation, but it failed to improve the chemotherapeutic property of the Dox-liposome. The i.v. injection of antp-liposomes (15\u2009mg Dox/kg) caused severe body weight loss and early death incidence due to probably increased toxicity. The antp targeting offered no advantage to the Dox-liposome in the delivery of Dox to the tumor, and failed to enhance the treatment efficiency of the liposomes."], "CopyrightInformation": "\u00a9 2021 American Institute of Chemical Engineers."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Kousani", "ForeName": "Sima", "Initials": "S"}, {"Identifier": ["0000-0002-0859-9658"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, Maryland, USA."}], "LastName": "Karimi", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnord, Iran."}], "LastName": "Teymouri", "ForeName": "Manouchehr", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Noncommunicable Disease Research Center, Bam University of Medical Sciences, Bam, Iran."}], "LastName": "Navashenaq", "ForeName": "Jamshid Gholizadeh", "Initials": "JG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Darban", "ForeName": "Shahrzad Amiri", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Jaafari", "ForeName": "Mahmoud Reza", "Initials": "MR"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Biotechnol Prog", "NlmUniqueID": "8506292", "ISSNLinking": "1520-6033"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antennapedia Homeodomain Protein"}, {"RegistryNumber": "0", "NameOfSubstance": "Peptides"}, {"RegistryNumber": "0", "NameOfSubstance": "liposomal doxorubicin"}, {"RegistryNumber": "3WJQ0SDW1A", "NameOfSubstance": "Polyethylene Glycols"}, {"RegistryNumber": "80168379AG", "NameOfSubstance": "Doxorubicin"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["genetics", "toxicity"], "DescriptorName": "Antennapedia Homeodomain Protein"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["analogs & derivatives", "chemistry", "pharmacokinetics", "toxicity"], "DescriptorName": "Doxorubicin"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Delivery Systems"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred BALB C"}, {"QualifierName": ["genetics", "metabolism", "toxicity"], "DescriptorName": "Peptides"}, {"QualifierName": ["chemistry", "pharmacokinetics", "toxicity"], "DescriptorName": "Polyethylene Glycols"}, {"QualifierName": [], "DescriptorName": "Tissue Distribution"}, {"QualifierName": ["drug effects"], "DescriptorName": "Weight Loss"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Console S, Marty C, Garc\u00eda-Echeverr\u00eda C, Schwendener R, Ballmer-Hofer K. Antennapedia and HIV transactivator of transcription (TAT)\u201cprotein transduction domains\u201d promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem. 2003;278(37):35109-35114."}, {"Citation": "Deshayes S, Morris M, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci CMLS. 2005;62(16):1839-1849."}, {"Citation": "Karimi M, Gheybi F, Zamani P, et al. Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: in vitro and in vivo anti-tumor study. Int J Pharm. 2020;580:119211."}, {"Citation": "Teymouri M, Badiee A, Golmohammadzadeh S, et al. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: an in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. Int J Pharm. 2016;511(1):236-244."}, {"Citation": "Darban SA, Badiee A, Jaafari MR. PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells. Nanomedicine. 2017;12(12):1475-1490."}, {"Citation": "Yuan W, Kuai R, Cai W, et al. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study. J Biomed Nanotechnol. 2014;10(8):1563-1573."}, {"Citation": "Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012;14(2):303-315."}, {"Citation": "Zarazvand F, Karimi M, Moosavian SA, et al. Efficacy comparison of TAT peptide-functionalized PEGylated liposomal doxorubicin in C26 and B16F0 tumor mice models. Int J Peptide Res Therapeut. 2021;1-11."}, {"Citation": "Grunwald J, Rejtar T, Sawant R, Wang Z, Torchilin VP. TAT peptide and its conjugates: proteolytic stability. Bioconjug Chem. 2009;20(8):1531-1537."}, {"Citation": "Sch\u00e4gger H. Tricine-sds-page. Nat Protoc. 2006;1(1):16-22."}, {"Citation": "Bolotin EM, Cohen R, Bar LK, et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res. 1994;4(1):455-479."}, {"Citation": "Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett. 2002;7(2):217-219."}, {"Citation": "Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234(3):466-468."}, {"Citation": "Teymouri M, Farzaneh H, Badiee A, Golmohammadzadeh S, Sadri K, Jaafari MR. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: in vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. Eur J Pharm Sci. 2015;80:66-73."}, {"Citation": "Strober W. Trypan blue exclusion test of cell viability. Curr Protocols Immunol. 2015;111(1):A3.B.1-A3.B.3."}, {"Citation": "Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55-63."}, {"Citation": "Huang Z, Szoka FC Jr. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc. 2008;130(46):15702-15712."}, {"Citation": "Huang Z, Jaafari MR, Szoka FC Jr. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angewandte Chemie. 2009;121(23):4210-4213."}, {"Citation": "Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12(5):1606-1614."}, {"Citation": "Allen T, Everest J. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J Pharmacol Exp Therapeut. 1983;226(2):539-544."}, {"Citation": "Hefesha H, Loew S, Liu X, May S, Fahr A. Transfer mechanism of temoporfin between liposomal membranes. J Control Release. 2011;150(3):279-286."}, {"Citation": "Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta (BBA)-Biomembranes. 2004;1665(1):48-56."}, {"Citation": "Barenholz YC. Doxil\u00ae-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134."}, {"Citation": "Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51(4):691-744."}, {"Citation": "Litzinger DC, Buiting AM, van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly (ethylene glycol)-containing liposomes. Biochim Biophys Acta (BBA)-Biomembranes. 1994;1190(1):99-107."}, {"Citation": "Mashreghi M, Faal Maleki M, Karimi M, Kalalinia F, Badiee A, Jaafari MR. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. J Drug Target. 2021;29(6):617-630."}, {"Citation": "Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta (BBA)-Biomembranes. 1989;981(1):27-35."}, {"Citation": "Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci. 1988;85(18):6949-6953."}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2021", "Month": "7", "Day": "18"}, {"Year": "2021", "Month": "3", "Day": "15"}, {"Year": "2021", "Month": "8", "Day": "11"}, {"Year": "2021", "Month": "8", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "18", "Hour": "6", "Minute": "54"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34405574", "10.1002/btpr.3202"]}}], "PubmedBookArticle": []}